Antonio Medina de Almeida


AuthID: R-000-T91

Confirmed Publications: 65



11
TITLE: Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
AUTHORS: Santini, V; Fenaux, P; Giagounidis, A; Platzbecker, U; List, AF; Haferlach, T; Zhong, J; Wu, CQ; Mavrommatis, K; Beach, CL; MacBeth, KJ; Almeida, A ;
PUBLISHED: 2020, SOURCE: LEUKEMIA, VOLUME: 35, ISSUE: 3
INDEXED IN: Scopus WOS CrossRef: 13
IN MY: ORCID | CIÊNCIAVITAE
12
TITLE: Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry  Full Text
AUTHORS: Hoeks, M; Yu, G; Langemeijer, S; Crouch, S; de Swart, L; Fenaux, P; Symeonidis, A; Cermak, J; Hellstrom Lindberg, E; Sanz, G; Stauder, R; Holm, MS; Mittelman, M; Madry, K; Malcovati, L; Tatic, A; Almeida, AM ; Germing, U; Savic, A; Simec, NG; Culligan, D; Itzykson, R; Guerci Bresler, A; Slama, B; van de Loosdrecht, A; van Marrewijk, C; Droste, J; Blijlevens, N; van Kraaij, M; Bowen, D; de Witte, T; Smith, A; ...More
PUBLISHED: 2020, SOURCE: HAEMATOLOGICA, VOLUME: 105, ISSUE: 3
INDEXED IN: Scopus WOS CrossRef: 32
IN MY: ORCID | CIÊNCIAVITAE
13
TITLE: Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis  Full Text
AUTHORS: Lopes Coelho, F; Silva, F; Gouveia Fernandes, S; Martins, C; Lopes, N; Domingues, G; Brito, C; Almeida, AM ; Pereira, SA; Serpa, J;
PUBLISHED: 2020, SOURCE: CELLS, VOLUME: 9, ISSUE: 1
INDEXED IN: Scopus WOS CrossRef: 34
IN MY: ORCID | CIÊNCIAVITAE
14
TITLE: Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
AUTHORS: de Witte, T; Malcovati, L; Fenaux, P; Bowen, D; Symeonidis, A; Mittelman, M; Stauder, R; Sanz, G; Cermak, J; Langemeijer, S; Hellstrom Lindberg, E; Germing, U; Holm, MS; Madry, K; Tatic, A; Almeida, AM ; Savic, A; Rogulj, IM; Itzykson, R; Hoeks, M; Garelius, HG; Culligan, D; Kotsianidis, I; Ades, L; van de Loosdrecht, AA; van Marrewijk, C; Yu, G; Crouch, S; Smith, A; ...More
PUBLISHED: 2020, SOURCE: HAEMATOLOGICA, VOLUME: 105, ISSUE: 11
INDEXED IN: Scopus WOS CrossRef: 12
IN MY: ORCID | CIÊNCIAVITAE
15
TITLE: Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial  Full Text
AUTHORS: Guillermo Garcia-Manero; Antonio Almeida ; Pierre Fenaux; Norbert Gattermann; Aristoteles Giagounidis; Stuart L Goldberg; Keiya Ozawa; Jerry Weaver; Valeria Santini;
PUBLISHED: 2019, SOURCE: Clinical Lymphoma Myeloma and Leukemia, VOLUME: 19, ISSUE: 4
INDEXED IN: CrossRef: 4
IN MY: ORCID | CIÊNCIAVITAE
16
TITLE: Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy
AUTHORS: Cerveira, N; Almeida, A ;
PUBLISHED: 2019, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 37, ISSUE: 1
INDEXED IN: Scopus WOS CrossRef: 2
IN MY: ORCID | CIÊNCIAVITAE
17
TITLE: Less iron improves MDS haematopoiesis
AUTHORS: Gyan, E; Almeida, AM ;
PUBLISHED: 2019, SOURCE: BRITISH JOURNAL OF HAEMATOLOGY, VOLUME: 187, ISSUE: 1
INDEXED IN: Scopus WOS CrossRef: 1
IN MY: ORCID | CIÊNCIAVITAE
18
TITLE: Negative MR4.0 chronic myeloid leukaemia and its possible implications for treatment-free remission  Full Text
AUTHORS: Nuno Cerveira; Joana Diamond; Sonia Matos; Maria L Amorim; Margarida Coucelo; Susana Bizarro; Ana Teresa Simoes; Francesca Pierdomenico; Mariana Lopes; Leticia Ribeiro; Maria do Carmo Fonseca; Jose E Guimaraes; Antonio Almeida ; Manuel R Teixeira ;
PUBLISHED: 2019, SOURCE: BRITISH JOURNAL OF HAEMATOLOGY, VOLUME: 186, ISSUE: 6
INDEXED IN: Scopus WOS CrossRef: 1
IN MY: ORCID | CIÊNCIAVITAE
19
TITLE: New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
AUTHORS: Almeida, AG ; Almeida, A ; Melo, T; Guerra, L; Lopes, L; Ribeiro, P; Duarte, M; Mota, A; Fontes Carvalho, R ;
PUBLISHED: 2019, SOURCE: REVISTA PORTUGUESA DE CARDIOLOGIA, VOLUME: 38, ISSUE: 1
INDEXED IN: Scopus WOS CrossRef: 1
IN MY: ORCID | CIÊNCIAVITAE
20
TITLE: Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available
AUTHORS: Foltz, L; Pica, GM; Zerazhi, H; Van Droogenbroeck, J; Visanica, S; de la Fuente, EB; Leber, B; de Almeida, AM ; Ranta, D; Kiladjian, JJ; Chrit, L; Kandra, A; Morando, J; Devos, T;
PUBLISHED: 2019, SOURCE: LEUKEMIA & LYMPHOMA, VOLUME: 60, ISSUE: 14
INDEXED IN: Scopus WOS CrossRef: 6
IN MY: ORCID | CIÊNCIAVITAE
Page 2 of 7. Total results: 65.

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service